




CALCITONIN DIRECTLY ATTENUATES COLLAGEN TYPE 
II DEGRADATION BY INHIBITION OF MMP EXPRESSION 
AND ACTIVITY IN ARTICULAR CHONDROCYTES 
BC Sondergaard 1, K Henriksen 2, H Wulf 2, S Ostergaard 1, P 
Qvist 1 , YZ Bagger 1 , C Christiansen 1, LB Tank61 , MA Karsdal 2 
1 Pharmacology and Biomarkers, Nordic Bioscience & Center for 
Clinical and Basic Research, Herlev, Denmark; 2 pharmos 
Bioscience, Herlev, Denmark 
Purpose: Calcitonin was recently shown to counter the pro- 
gression of cartilage degradation in experimental models of os- 
teoarthritis. The beneficial effect was believed mediated indirectly 
by inhibition of subchondral bone resorption. We investigated 
whether calcitonin has direct effect on articular cartilage chon- 
drocytes. 
Methods: The Iocalisation and expression of the calcitonin re- 
ceptor in articular chondrocytes was investigated by immunhisto- 
chemistry and RT-PCR. Potential direct effects was tested in the 
articular cartilage explants model, where cartilage degradation 
was induced by cytokine stimulation of TNF-~ [20ng/ml] + onco- 
statin M (OSM) [10ng/ml], and cultured with salmon or human 
calcitonin simultaneously [0.0001-1mM]. The changes in carti- 
lage degradation were investigated in the conditioned medium by 
quantification of C-terminal telopeptides of collagen type II (CTX- 
II) and sulphated glycosaminoglycans release (sGAG) was tested 
by the Wielisa®-Kit. The effect of calcitonin was investigated in 
vivo using rats. Rats were administered with an oral dose of cal- 
citonin (2 mg/kg) bound to the carrier 5-CNAC (150 mg/kg). Colla- 
gen type II degradation was quantified in serum by measuring the 
released CTX-II and the degradation of bone by CTX-I, a marker 
of bone resorption, measuring fragments of collagen type I. 
Results: The calcitonin receptor was identified on articular chron- 
drocytes, both mRNA and protein forms. Culturing articular car- 
tilage explants in the presence of TNF-a and OSM resulted in a 
marked, 100-fold increase in CTX-II release compared to vehicle- 
treated controls (p<0.001). Addition of human or salmon calci- 
tonin to the explants culture [0.0001-1mM] in the concomitant 
presence of TNF-~ and OSM resulted in a significant and dose 
dependent inhibition of CTX-II release (p<0.01). At 100 nm and 
1 mM of calcitonin treatment in the presence of OSM and TNF- 
~, calcitonin very nearly abrogated collagen type II release, at 
day 13,16 and 19 of culture. In the absence of OSM and TNF- 
~, calcitonin significantly inhibited GAG release into the condi- 
tioned medium. Proteolytic activity was investigated by zymogra- 
phy. TNF-~ and OSM resulted in a strong up regulation of MMP- 
9 activity and expression. This increase in MMP activity was 
strongly attenuated by calcitonin at 100 nM and 1 mM, and the 
positive control GM6001 [25 mM], a the general MMP inhibitor, 
Under in vivo conditions, 4-day oral treatment with calcitonin in- 
duced a 95% decrease in serum CTX-II levels, i.e. chondrocyte- 
mediated cartilage degradation. The parallel effects of calcitonin 
treatment on bone resorption was indicated by a 50% decrease 
in urinary CTX-I excretion. 
Conclusions: These results suggest that calcitonin 1) acts di- 
rectly on articular chondrocytes; 2) inhibits MMP expression and 
the related collagen type II degradation; and 3) carries potentials 
for becoming a useful therapeutical option for patients with de- 
generative joint diseases. 
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GADD451~ IS NOVEL MEDIATOR OF MMP-13 GENE 
EXPRESSION DURING CHONDROCYTE HYPERTROPHY 
K Ijiri 1 , LF Zerbini 1 , H Peng 1 , N Walsh 1 , XL Huang 1 , H Otu 1 , B 
Lu 2, TA Libermann 1, MB Goldring 1 
1New England Baptist Bone & Joint Institute, Beth Israel 
Deaconess Medical Center, Boston, MA; 2Department of 
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Aim of Study: To define the role of growth arrest and DNA 
damage-inducible 451~ (GADD451~) in the regulation of chondro- 
cyte differentiation i the embryonic growth plate. 
Methods: Immortalized human chondrocytes (C-28/12) were 
treated with BMP-2 at 100 ng/ml for 1 h and total RNA was 
analyzed on the Affymetrix Gene Chip Human Genome U133A 
microarray and the highly expressed genes were confirmed in 
C28/12 cells and primary human chondrocytes by real-time PCR. 
ATDC5 cells and pellet cultures of murine rib growth plate chon- 
drocytes were grown under defined conditions as models of chon- 
drogenesis. Lentiviral siRNA delivery was performed to knock- 
down GADD451~ and the pcDNA3-Gadd451~-flag expression vec- 
tor was used to overexpress GADD451~. GADD451~ and MMP-13 
promoter activities were assessed using luciferase reporter con- 
structs. Mouse embryonic growth plates were examined by im- 
munohistochemistry and in situ hybridization. 
Results: We identified GADD451~ as a prominent early response 
gene induced by BMP-2 through a Smadl/Runx2-dependent 
pathway. Since this pathway is involved in skeletal development, 
we examined embryonic growth plates and observed expres- 
sion of GADD451~ mRNA coincident with Runx2 protein in pre- 
hypertrophic hondrocytes, whereas GADD451~ protein was local- 
ized in the nucleus in late stage hypertrophic hondrocytes where 
Mmp13 mRNA was expressed. In Gadd451~ knockout mouse 
embryos, defective mineralization and decreased endochondral 
growth accompanied eficient Mmpl 3 and Coll 0al gene expres- 
sion in the hypertrophic zone. Transduction of siRNA-GADD451~ 
in epiphyseal chondrocytes in vitro blocked terminal differenti- 
ation and the associated expression of Mmp13 and Coll0al 
mRNA. Finally, GADD451~ stimulated MMP-13 promoter activity 
in chondrocytes through c-Jun N-terminal kinase (JNK)-mediated 
phosphorylation of JunD partnered with Fra2 in synergy with 
Runx2. 
Discussion: Our results demonstrate a previously undiscovered 
role for GADD451~, which has been implicated in the stress re- 
sponse and cell survival during terminal differentiation of other 
cell types, as a critical mediator during endochondral ossifica- 
tion. The intracellular accumulation of GADD451~ protein in intact 
hypertrophic hondrocytes in the mouse embryonic growth plate 
and the effects of GADD451~ deficiency in vivo and in vitro indicate 
that GADD451~ is required for MMP-13 expression during the later 
stages of chondrocyte hypertrophy. Our findings on Runx2 syn- 
ergy provide a new concept regarding a temporal and spatial link 
between BMP-2-induced GADD451~ and the induction of MMP-13 
gene transcription via the JNK/JunD pathway at terminal stages. 
Furthermore, as we reported previously, GADD451~ is expressed 
in normal cartilage, increased in early stage osteoarthritis (OA), 
and decreased in late stage OA, particularly in the deep, calci- 
fied zone, where it may serve as an anti-apoptotic signal in cells 
with features of hypertrophic hondrocytes, suggesting a role in 
tidemark advancement. 
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Abstract A4 - Table 1 
Placebo (N=104) Acetaminophen (N=108) Glucosamine sulfate (N=106) 
Baseline 6 months Baseline 6 months Baseline 6 months 
Lequesne (points)a 10.8 (2.6) -1.9 (-2.6 to -1.2) 11.1 (2.7) -2.7 (-3.3 to -2.1) 11.0 (3.1) -3.1" (-3.8 to -2.3) 
WOMAC (points)a 37.9 (14.3) -8.2 (-11.3 to -5.1) 40.4 (14.8) -12.3 (-14.9 to -9.7) 38.3 (15.2) -12.91 (-15.6 to -10.1) 
OARSI-A responders (%) - 21.2% 33.3%~: 39.6%§ 
a Mean absolute (SD) at baseline and change (95%CI) at 6 months. P vs placebo: *0.032 [difference = -1.2 (-2.3 to -0.8)]; 10.039 [difference = -4.7 (-9.1 to -0.2)]; 
~:0.047; §0.007 
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THE CATABOLIC PATHWAY MEDIATED BY TOLL-LIKE 
RECEPTORS IN CHONDROCYTES 
HA Kim 1 , HY Choi 1 , CS Yoon 1 , ML Cho 2, JY Jhun 2, HJ Oh 2, 
HY Kim 2 
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Anyang, Kyunggi, Korea; 2Rheumatism Research Center, 
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Purpose: To define the role of Toll-like receptor(TLR) mediated 
signaling in the catabolic pathway in cultured human articular 
chondrocytes. 
Methods: Cartilage samples were obtained from OA and femur 
neck fracture patients and chondrocytes were cultured in both 
monolayer and explant. For evaluation of the expression of TLR 
in cartilage specimens, immunohistochemistry for TLR-2 and 4 
were performed. Regulation of TLR expression in cultured chon- 
drocytes was observed by RT-PCR. For stimulation of TLR2 and 
4, chondrocytes were treated with Staphylococcus aureus pep- 
tidoglycan(PGN) and liposaccharides (LPS), as TLR2 and 4 lig- 
ands, respectively. Production of MMP-1,3, 13 and prostaglandin 
(PG) E2 was evaluated by ELISA assay. Production of nitric ox- 
ide (NO) was analyzed by Griess reaction. Phosphorylation of 
JNK and NF-kB activation were observed with Western blot and 
electrophoretic mobility shift assay, respectively. 
Results: Expression of TLR 2, and 4 was upregulated in lesion 
area of OA cartilage. Treatment with interleukin-1, tumor necro- 
sis factor-alpha, PGN and LPS all significantly upregulated both 
TLR2 and TLR4 expression in cultured chondrocytes. Production 
of MMP-1, 3, and 13, NO and PGE2 significantly increased af- 
ter treating chondrocytes with either PGN or LPS, which was 
inhibited by anti-TLR antibodies. Treatment with PGN and LPS 
led to phosphorylation of JNK and activation of NF-kB. Pretreat- 
ment of chondrocytes with JNK inhibitor SP600125 and NF-kB 
inhibitor, MG132 led to significant downregulation of all catabolic 
responses mediated by TLR ligands. 
Conclusion: TLR ligands function as stimulants of chondrocyte 
catabolism. TLR mediated signaling may play an important role in 
the cartilage degradation in rheumatoid and osteoarthritis. Eluci- 
dation of endogenous TLR ligands working as a catabolic stimuli 
on chondorcytes is the subject of further research. 
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EFFECTS OF GLUCOSAMINE SULFATE ON 6-MONTH 
CONTROL OF KNEE OSTEOARTHRITIS SYMPTOMS VS 
PLACEBO AND ACETAMINOPHEN: RESULTS FROM THE 
GLUCOSAMINE UNUM IN DIE EFFICACY (GUIDE)TRIAL 
G Herrero-Beaumont 1 , JA Rom~.n 2, MC Trabado 3, FJ Blanco 4, 
P Benito 5, E Martin-Mola 6, J Paulino 7, JL Marenco 8, A Porto 9, 
A Laffon 1°, D Araejo 11 , M Figueroa 12, J Branco 13 
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3H Clinic, Barcelona; 4CH Juan Canalejo, A Coruha; 5H del Mar, 
Barcelona; 6H U La Paz, Madrid; 7C H C R, Ciudad Real; 8H 
N.S. de Valme, Sevilla 9H U, Coimbra; l°H Princesa, Madrid; 11H 
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Aim of Study: Two multicenter, randomised, placebo-controlled, 
double-blind trials lately investigated the efficacy of oral glu- 
cosamine in knee osteoarthritis (OA), using a symptomatic med- 
ication as reference: GAIT performed by the NIH in the US with 
nutraceutical glucosamine hydrochloride 500 mg t.i.d, vs cele- 
coxib, and GUIDE performed in Europe with the prescription 
glucosamine sulfate (GS) 1500 mg once-a-day (u.i.d.) vs ac- 
etaminophen, i.e. the preferred symptomatic medication in OA 
practice guidelines. We report the results of GUIDE. 
Methods: 318 patients (88% women) with knee OA (ACR crite- 
ria) were randomised to double-dummy oral GS soluble powder 
1500 mg u.i.d., or acetaminophen 1000 mg tablets t.i.d. (3 g/day, 
as recommended in Europe), or placebo for 6 months. The res- 
cue medication consisted of standardised use of ibuprofen 400 
mg tablets (daily diary recording). The primary efficacy parame- 
ter was the ITT 6-month change in the Lequesne index, using the 
LOCF approach for patients not completing the study according 
to the protocol (34 on placebo, 28 in each the acetaminophen 
and GS groups, without differences in drop-out reasons). Sec- 
ondary efficacy parameters included the WOMAC index and the 
OARSI-A responder criteria. Analysis on the indexes was per- 
formed by GLM-ANOVA, with Dunnett's pairwise comparisons vs 
placebo. The proportions of responders and patients using the 
rescue medication were compared by the chi-square test. 
Results: The groups were comparable for demographics and 
baseline disease characteristics. GS efficacy vs placebo was sig- 
nificant on all parameters (Table 1). Acetaminophen had more 
responders than placebo, but it failed to reach a significant differ- 
ence on the Lequesne (p=0.18) and WOMAC (p=0.077) indexes. 
More patients on placebo used the rescue medication (p=0.027 
and 0.045 vs GS and acetaminophen, respectively). There were 
no differences among groups in safety. 
Conclusions: Glucosamine sulfate at the oral once-daily dose of 
1500 mg might be the preferred symptomatic medication in knee 
OA. 
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RISEDRONATE PROTECTS AGAINST SUBCHONDRAL 
BONE LOSS IN OA KNEE PATIENTS WITH 
PROGRESSIVE JOINT SPACE NARROWING 
JC Buckland-Wright 1 , EA Messent 1 , GA Cline 2, JF Beary 2, JM 
Meyer 2 
1Applied Clinical Anatomy, King's College London, London, 
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Aim of Study: Subchondral trabecular bone loss is character- 
istic of progressive knee OA (Messent et al, Osteoarthritis Cart 
2005;13:463-70). This study determined whether risedronate, a 
bisphosphonate, slowed this loss of bone within the proximal tibia 
of patients with medial compartment disease. 
Methods: 100 patients were randomly selected from each treat- 
ment group (each N~300) comprising placebo, and risedronate 
5mg qd, 15mg qd and 50mg qwk from a large double blind, mul- 
ticenter, placebo-controlled 2-year investigation of patients with 
knee OA, joint space width (JSW) between 2-4 mm, at least one 
osteophyte present and knee pain most days of 1 month in last 
